Graft-versus-host Disease Clinical Trial
Official title:
A Phase IB-II Study Of High-Dose Post-Transplant Cyclophosphamide, Abatacept, and Short-Duration Tacrolimus for the Prevention of Graft-Versus-Host Disease (GvHD) Following Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
This is a single arm, open label, optimal 2-stage Simon design phase Ib-II clinical trial. Adult patients with hematological malignancies undergoing allogeneic HSCT from first- or second-degree haploidentical donor are eligible for the study if they meet the standard criteria defined in our institutional standard operation procedures (SOPs), meet all inclusion criteria, and do not satisfy any exclusion criteria. Patients will receive non-myeloablative, reduced-intensity or myeloablative conditioning regimen followed by peripheral blood hematopoietic stem cells. Patients will receive cyclophosphamide, abatacept, and short-duration tacrolimus for GvHD prophylaxis.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT01428973 -
Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens
|
Phase 2 | |
| Not yet recruiting |
NCT00749164 -
Allogeneic Mesenchymal Stem Cell for Graft-Versus-Host Disease Treatment
|
Phase 1/Phase 2 | |
| Completed |
NCT00993343 -
Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation
|
Phase 3 | |
| Completed |
NCT00360685 -
Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX
|
N/A | |
| Terminated |
NCT02080195 -
Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)
|
Phase 1/Phase 2 | |
| Completed |
NCT02193880 -
Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)
|
N/A | |
| Completed |
NCT02942173 -
CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT
|
Phase 2/Phase 3 | |
| Completed |
NCT02145403 -
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01941394 -
Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation
|
Phase 2 | |
| Completed |
NCT00141713 -
The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease
|
Phase 2 | |
| Recruiting |
NCT01991301 -
Carfilzomib for the Prevention of Graft Versus Host Disease
|
Phase 1 | |
| Completed |
NCT00408928 -
Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease
|
Phase 2 | |
| Completed |
NCT01633229 -
Bone Marrow Stromal Cell Infusions for Stem Cell Transplant Complications
|
Phase 1 | |
| Completed |
NCT05856058 -
To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability
|
Phase 1 | |
| Completed |
NCT02342613 -
Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
|
Phase 1 | |
| Recruiting |
NCT06423131 -
Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT
|
N/A | |
| Completed |
NCT02144025 -
Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT
|
Phase 2 | |
| Completed |
NCT01369914 -
The Natural History of Graft-Versus-Host Disease in the Eyes
|
||
| Completed |
NCT00806728 -
Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease
|
Phase 1 | |
| Completed |
NCT01851382 -
Collection of Saliva and/ or Peripheral Blood From Healthy Volunteers for Research
|